We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Labcorp Debuts First FDA-Cleared Blood Test for Alzheimer's, Stock Up
Read MoreHide Full Article
Key Takeaways
Labcorp introduced the first FDA-cleared blood test to aid in diagnosing Alzheimer's disease.
LH's Lumipulse test delivers results comparable to CSF and PET scans with a simple blood draw.
LH's launch aligns with new guidelines endorsing blood-based biomarkers in Alzheimer's care.
Labcorp Holdings, Inc. (LH - Free Report) has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in diagnosing Alzheimer's disease. Developed by Fujirebio Diagnostics, Inc., the test helps through early detection of the amyloid plaques associated with the disease in appropriate patients.
The latest test builds on and replaces a similar pTau-217/Beta Amyloid 42 Ratio test that Labcorp introduced in April 2025.
Likely Trend of LH Stock Following the News
Following the announcement yesterday, Labcorp shares edged up 0.04%, finishing at $270.49. The path to an Alzheimer's diagnosis has generally involved years of invasive procedures and expensive imaging, prompting the need for faster diagnosis of patients, enrolling in clinical trials, or starting therapies. By offering this FDA-cleared blood test across the nation, the company is playing a key role in delivering innovative solutions for Alzheimer's disease and other neurological conditions by helping patients, families and physicians get answers sooner. We expect the market sentiment toward LH stock to remain positive surrounding this news.
Labcorp has a market capitalization of $22.47 billion. Going by the Zacks Consensus Estimate, the company’s earnings are expected to grow 11.9% in 2025, over a 7.7% increase in revenues. In the trailing four quarters, it delivered an average earnings beat of 2.5%.
More on Labcorp’s New Offering
The Lumipulse pTau-217/Beta Amyloid 42 Ratio offers results comparable to current methods for diagnosis of Alzheimer's disease — cerebrospinal fluid (CSF) testing obtained through lumbar puncture and positron emission tomography (PET) scans — but from a simple blood draw, making it more affordable, more accessible and less invasive. In clinical studies, Fujirebio reported that the test demonstrated a positive predictive value of 92% and a negative predictive value of 97%.
The launch of this test closely follows the release of a new clinical guideline from the Alzheimer's Association, which supports the use of blood-based biomarkers to help evaluate patients suspected of Alzheimer's disease in specialty care settings. The guideline reflects the growing clinical consensus around these tools and underscores the need for expanding access.
Image Source: Zacks Investment Research
The Lumipulse pTau-217/Beta Amyloid 42 Ratio is designed for adults aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline. It is not a screening or stand-alone diagnostic test and ought to be interpreted in conjunction with other clinical information of the patient. Once ordered, patients can complete the blood draw in a healthcare provider's office or any of Labcorp's more than 2,200 Patient Service Centers nationwide.
Industry Prospects Back LH
Per a research report, the global Alzheimer’s disease diagnostics market was valued at $8.33 billion in 2024 and is likely to witness a compound annual growth rate of 11% through 2030. Some of the key factors fueling the market’s growth are the increasing prevalence of Alzheimer’s disease, growing adoption of personalized products and increasing technological advancements in medical imaging.
Other Developments at Labcorp
Last month, Labcorp launched Test Finder, a first-of-its-kind generative AI tool developed with Amazon Web Services. Designed to simplify lab test selection, Test Finder enables healthcare providers to ask questions or describe conditions in plain language and receive curated test recommendations, enhancing the user experience and freeing up more time for patient care.
LH Stock Price Performance
Over the past year, Labcorp shares have rallied 19.8% compared with the industry’s 18.3% rise.
Estimates for Envista’s 2025 earnings per share have increased 7.6% in the past 30 days. Shares of the company have rallied 16.7% in the past year compared to the industry’s 5.2% rise. Its earnings yield of 5.4% also outpaced the industry’s -0.9% yield. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
Boston Scientific shares have rallied 31.3% in the past year. Estimates for the company’s 2025 earnings per share have increased 2.4% to $2.98 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 8.1%. In the last reported quarter, it posted an earnings surprise of 4.2%.
Estimates for IDEXX Laboratories’ 2025 earnings per share have climbed 3.1% to $12.55 in the past 30 days. Shares of the company have jumped 29.1% in the past year against the industry’s 14% fall. IDEXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.1%. In the last reported quarter, it delivered an earnings surprise of 9.7%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Labcorp Debuts First FDA-Cleared Blood Test for Alzheimer's, Stock Up
Key Takeaways
Labcorp Holdings, Inc. (LH - Free Report) has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in diagnosing Alzheimer's disease. Developed by Fujirebio Diagnostics, Inc., the test helps through early detection of the amyloid plaques associated with the disease in appropriate patients.
The latest test builds on and replaces a similar pTau-217/Beta Amyloid 42 Ratio test that Labcorp introduced in April 2025.
Likely Trend of LH Stock Following the News
Following the announcement yesterday, Labcorp shares edged up 0.04%, finishing at $270.49. The path to an Alzheimer's diagnosis has generally involved years of invasive procedures and expensive imaging, prompting the need for faster diagnosis of patients, enrolling in clinical trials, or starting therapies. By offering this FDA-cleared blood test across the nation, the company is playing a key role in delivering innovative solutions for Alzheimer's disease and other neurological conditions by helping patients, families and physicians get answers sooner. We expect the market sentiment toward LH stock to remain positive surrounding this news.
Labcorp has a market capitalization of $22.47 billion. Going by the Zacks Consensus Estimate, the company’s earnings are expected to grow 11.9% in 2025, over a 7.7% increase in revenues. In the trailing four quarters, it delivered an average earnings beat of 2.5%.
More on Labcorp’s New Offering
The Lumipulse pTau-217/Beta Amyloid 42 Ratio offers results comparable to current methods for diagnosis of Alzheimer's disease — cerebrospinal fluid (CSF) testing obtained through lumbar puncture and positron emission tomography (PET) scans — but from a simple blood draw, making it more affordable, more accessible and less invasive. In clinical studies, Fujirebio reported that the test demonstrated a positive predictive value of 92% and a negative predictive value of 97%.
The launch of this test closely follows the release of a new clinical guideline from the Alzheimer's Association, which supports the use of blood-based biomarkers to help evaluate patients suspected of Alzheimer's disease in specialty care settings. The guideline reflects the growing clinical consensus around these tools and underscores the need for expanding access.
Image Source: Zacks Investment Research
The Lumipulse pTau-217/Beta Amyloid 42 Ratio is designed for adults aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline. It is not a screening or stand-alone diagnostic test and ought to be interpreted in conjunction with other clinical information of the patient. Once ordered, patients can complete the blood draw in a healthcare provider's office or any of Labcorp's more than 2,200 Patient Service Centers nationwide.
Industry Prospects Back LH
Per a research report, the global Alzheimer’s disease diagnostics market was valued at $8.33 billion in 2024 and is likely to witness a compound annual growth rate of 11% through 2030. Some of the key factors fueling the market’s growth are the increasing prevalence of Alzheimer’s disease, growing adoption of personalized products and increasing technological advancements in medical imaging.
Other Developments at Labcorp
Last month, Labcorp launched Test Finder, a first-of-its-kind generative AI tool developed with Amazon Web Services. Designed to simplify lab test selection, Test Finder enables healthcare providers to ask questions or describe conditions in plain language and receive curated test recommendations, enhancing the user experience and freeing up more time for patient care.
LH Stock Price Performance
Over the past year, Labcorp shares have rallied 19.8% compared with the industry’s 18.3% rise.
LH’s Zacks Rank and Top MedTech Stocks
Labcorp currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space include Envista (NVST - Free Report) , Boston Scientific (BSX - Free Report) and IDEXX Laboratories (IDXX - Free Report) . While Envista sports a Zacks Rank #1 (Strong Buy), Boston Scientific and IDEXX Laboratories each carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Envista’s 2025 earnings per share have increased 7.6% in the past 30 days. Shares of the company have rallied 16.7% in the past year compared to the industry’s 5.2% rise. Its earnings yield of 5.4% also outpaced the industry’s -0.9% yield. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
Boston Scientific shares have rallied 31.3% in the past year. Estimates for the company’s 2025 earnings per share have increased 2.4% to $2.98 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 8.1%. In the last reported quarter, it posted an earnings surprise of 4.2%.
Estimates for IDEXX Laboratories’ 2025 earnings per share have climbed 3.1% to $12.55 in the past 30 days. Shares of the company have jumped 29.1% in the past year against the industry’s 14% fall. IDEXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.1%. In the last reported quarter, it delivered an earnings surprise of 9.7%.